Kezar Life Sciences, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of John Franklin Fowler. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate John Franklin Fowler has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KZR / Kezar Life Sciences, Inc. CEO, Director 393,904
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by John Franklin Fowler. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KZR / Kezar Life Sciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KZR / Kezar Life Sciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-02-04 KZR Fowler John Franklin 38,461 2.6000 3,846 26.0000 99,999 121 7.75 -70,192 -70.19
2019-10-10 KZR Fowler John Franklin 1,000 3.2354 100 32.3540 3,235
2019-08-13 KZR Fowler John Franklin 2,000 4.6550 200 46.5500 9,310
2019-08-09 KZR Fowler John Franklin 500 5.2550 50 52.5500 2,628
2019-08-09 KZR Fowler John Franklin 750 5.0147 75 50.1470 3,761

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insider Sales KZR / Kezar Life Sciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KZR / Kezar Life Sciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by John Franklin Fowler as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-11-14 2022-11-10 4 KZR Kezar Life Sciences, Inc.
Common Stock
M - Exercise 27,000 393,904 7.36 0.90 24,300 354,514
2022-01-07 2022-01-05 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 500,000 500,000
2021-12-15 2021-12-14 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 82,721 -8.52
2021-12-15 2021-12-14 4 KZR Kezar Life Sciences, Inc.
Common Stock
M - Exercise 7,700 366,904 2.14 0.90 6,930 330,214
2021-01-11 2021-01-08 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 1,200,000 1,200,000
2021-01-04 2020-12-31 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -16,000 90,421 -15.03
2021-01-04 2020-12-31 4 KZR Kezar Life Sciences, Inc.
Common Stock
M - Exercise 16,000 359,204 4.66 0.90 14,400 323,284
2020-02-05 2020-02-04 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 38,461 38,461 2.60 99,999 99,999
2020-01-13 2020-01-12 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 200,000 200,000
2019-12-20 2019-12-19 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -50,000 106,421 -31.97
2019-12-20 2019-12-19 4 KZR Kezar Life Sciences, Inc.
Common Stock
M - Exercise 50,000 346,954 16.84 0.90 45,000 312,259
2019-10-11 2019-10-10 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 1,000 296,954 0.34 3.24 3,235 960,765
2019-08-14 2019-08-13 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 2,000 295,954 0.68 4.66 9,310 1,377,666
2019-08-12 2019-08-09 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 750 293,954 0.26 5.01 3,761 1,474,091
2019-08-12 2019-08-09 4 KZR Kezar Life Sciences, Inc.
Common Stock
P - Purchase 500 293,204 0.17 5.26 2,628 1,540,787
2019-01-08 2019-01-06 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (right to buy)
A - Award 175,000 175,000
2018-06-27 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Employee Stock Option (Right to Buy)
A - Award 88,967 88,967
2018-06-20 3 KZR Kezar Life Sciences, Inc.
Common Stock
585,408
2018-06-20 3 KZR Kezar Life Sciences, Inc.
Common Stock
585,408
2018-06-20 3 KZR Kezar Life Sciences, Inc.
Common Stock
585,408
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)